

# Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

NCT06047977

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	H. Lee Moffitt Cancer Center and Research Institute
<b>Enrollment</b>	30 participants

## Key Eligibility Criteria

---

### Inclusion (48)

- Part One (Prospective biobanking study):
- Patients must be e1 year to d 21 years of age at time of enrollment to Part One.
- Initial therapy patients: Patients with a histologic diagnosis of high-risk pediatric malignant solid tumors (pMST), defined as a pediatric malignant solid tumor outside of the central nervous system, newly-diagnosed or being treated with initial therapy, with expected 5-year Event-Free Survival (EFS) \<60%. Examples include:
  - High-risk neuroblastoma
  - Metastatic Ewing sarcoma
- ... and 43 more (see full listing online)

### Exclusion (11)

- Part Two:
- Patients with active systemic infections requiring intravenous antibiotics
- Patients testing positive for HIV titer, hepatitis B surface antigen, human T-cell leukemia-lymphoma virus (HTLV) I or II antibody, or both rapid plasma regain (RPR) and fluorescent treponemal antibody (FTA) are excluded. Patients with hepatitis C antibody must have a negative (undetectable) viral load by polymerase chain reaction (PCR).
- Patients who are pregnant or nursing.
- Sexually active patients of reproductive potential are eligible if they have agreed to use an effective contraceptive method from the time of informed consent through the duration and for 1 month following completion of protocol treatment. The definition of an effective contraceptive method will be at the discretion of the institutional investigator.
- ... and 6 more (see full listing online)

## Locations (1 total)

---

Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States